科學家開發出可用於PET成像的放射性同位素
作者:
小柯機器人發布時間:2020/12/17 15:53:00
美國加州大學伯克利分校Rebecca J. Abergel等研究人員合作開發出可用於PET成像的放射性同位素。2020年12月14日,《自然—化學》雜誌在線發表這一研究論文。
研究人員表示,開發靶向性的α射線療法具有改變疾病治療方式的潛力。在這些幹預措施中,靶向載體用發射α的放射性同位素標記,該放射性同位素將破壞性輻射離散地傳遞給患病細胞,同時又保留了周圍的健康組織。這一方法的廣泛使用需要無創成像技術的進步。為此,正電子發射斷層掃描(PET)成像已成為最有用的診斷技術之一。不幸的是,許多有前途的α-放射性同位素與PET成像不兼容,例如225Ac和227Th。
研究人員通過開發134Ce的大規模(Ci規模)生產和純化方法克服了這一障礙。隨後在一個小動物模型中進行的放射性標記和體內PET成像實驗表明,134Ce(及其134La子體)可以用作225AcIII(還原的134CeIII)或227ThIV(氧化的134CeIV)的PET成像候選物。
與X射線吸收光譜法結果一起評估這些數據,研究人員證明了如何依賴於嚴格控制CeIII/CeIV氧化還原對來成功實現這一目的。
附:英文原文
Title: Developing the 134 Ce and 134 La pair as companion positron emission tomography diagnostic isotopes for 225 Ac and 227 Th radiotherapeutics
Author: Tyler A. Bailey, Veronika Mocko, Katherine M. Shield, Dahlia D. An, Andrew C. Akin, Eva R. Birnbaum, Mark Brugh, Jason C. Cooley, Jonathan W. Engle, Michael E. Fassbender, Stacey S. Gauny, Andrew L. Lakes, Francois M. Nortier, Ellen M. OBrien, Sara L. Thiemann, Frankie D. White, Christiaan Vermeulen, Stosh A. Kozimor, Rebecca J. Abergel
Issue&Volume: 2020-12-14
Abstract: Developing targeted α-therapies has the potential to transform how diseases are treated. In these interventions, targeting vectors are labelled with α-emitting radioisotopes that deliver destructive radiation discretely to diseased cells while simultaneously sparing the surrounding healthy tissue. Widespread implementation requires advances in non-invasive imaging technologies that rapidly assay therapeutics. Towards this end, positron emission tomography (PET) imaging has emerged as one of the most informative diagnostic techniques. Unfortunately, many promising α-emitting isotopes such as 225Ac and 227Th are incompatible with PET imaging. Here we overcame this obstacle by developing large-scale (Ci-scale) production and purification methods for 134Ce. Subsequent radiolabelling and in vivo PET imaging experiments in a small animal model demonstrated that 134Ce (and its 134La daughter) could be used as a PET imaging candidate for 225AcIII (with reduced 134CeIII) or 227ThIV (with oxidized 134CeIV). Evaluating these data alongside X-ray absorption spectroscopy results demonstrated how success relied on rigorously controlling the CeIII/CeIV redox couple.
DOI: 10.1038/s41557-020-00598-7
Source: https://www.nature.com/articles/s41557-020-00598-7